117 related articles for article (PubMed ID: 23691553)
1. Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wilkins MR; Wang D; Li M; Stenmark KR; McKinsey TA; Buttrick P
Circulation; 2013 Apr; 127(14):e540. PubMed ID: 23691553
[No Abstract] [Full Text] [Related]
2. Letter by Bogaard et al regarding article, "histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid".
Bogaard HJ; Mizuno S; Voelkel NF
Circulation; 2013 Apr; 127(14):e539. PubMed ID: 23569123
[No Abstract] [Full Text] [Related]
3. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
6. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.
Gu W; Nusinzon I; Smith RD; Horvath CM; Silverman RB
Bioorg Med Chem; 2006 May; 14(10):3320-9. PubMed ID: 16434199
[TBL] [Abstract][Full Text] [Related]
7. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats.
Bogaard HJ; Mizuno S; Hussaini AA; Toldo S; Abbate A; Kraskauskas D; Kasper M; Natarajan R; Voelkel NF
Am J Respir Crit Care Med; 2011 May; 183(10):1402-10. PubMed ID: 21297075
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.
Phiel CJ; Zhang F; Huang EY; Guenther MG; Lazar MA; Klein PS
J Biol Chem; 2001 Sep; 276(39):36734-41. PubMed ID: 11473107
[TBL] [Abstract][Full Text] [Related]
9. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
10. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
Strobl JS; Cassell M; Mitchell SM; Reilly CM; Lindsay DS
J Parasitol; 2007 Jun; 93(3):694-700. PubMed ID: 17626366
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
Singh T; Prasad R; Katiyar SK
Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
[TBL] [Abstract][Full Text] [Related]
12. Histone modifications regulate the norepinephrine transporter gene.
Bayles R; Baker E; Eikelis N; El-Osta A; Lambert G
Cell Cycle; 2010 Nov; 9(22):4600-1. PubMed ID: 21088495
[No Abstract] [Full Text] [Related]
13. Regulation of the HIF-1alpha stability by histone deacetylases.
Kim SH; Jeong JW; Park JA; Lee JW; Seo JH; Jung BK; Bae MK; Kim KW
Oncol Rep; 2007 Mar; 17(3):647-51. PubMed ID: 17273746
[TBL] [Abstract][Full Text] [Related]
14. [A new target of cancer therapy: advances in the study of histone deacetylase].
Liu AL; Long J; Wang N; Du GH
Yao Xue Xue Bao; 2005 Jul; 40(7):585-90. PubMed ID: 16196262
[No Abstract] [Full Text] [Related]
15. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic cancer therapy makes headway.
Mack GS
J Natl Cancer Inst; 2006 Oct; 98(20):1443-4. PubMed ID: 17047192
[No Abstract] [Full Text] [Related]
17. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Landreville S; Agapova OA; Matatall KA; Kneass ZT; Onken MD; Lee RS; Bowcock AM; Harbour JW
Clin Cancer Res; 2012 Jan; 18(2):408-16. PubMed ID: 22038994
[TBL] [Abstract][Full Text] [Related]
18. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases?
Hoffmann K; Czapp M; Löscher W
Epilepsy Res; 2008 Oct; 81(2-3):107-13. PubMed ID: 18538545
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis.
Rao M; Valentini D; Zumla A; Maeurer M
Int J Infect Dis; 2018 Apr; 69():78-84. PubMed ID: 29501835
[TBL] [Abstract][Full Text] [Related]
20. Regulation of acetylation restores proteolytic function of diseased myocardium in mouse and human.
Wang D; Fang C; Zong NC; Liem DA; Cadeiras M; Scruggs SB; Yu H; Kim AK; Yang P; Deng M; Lu H; Ping P
Mol Cell Proteomics; 2013 Dec; 12(12):3793-802. PubMed ID: 24037710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
